CHOP intensification: not yet state of the art

Affiliations

Comment

Michael Pfreundschuh. Lancet Oncol. 2013 May.

. 2013 May;14(6):445-7.

doi: 10.1016/S1470-2045(13)70156-6. Epub 2013 Apr 9.

¹ Saarland University Medical School, Homburg, Saarland, Germany. michael.pfreundschuh@uks.eu

No abstract available

Comment on

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A. Delarue R, et al. Lancet Oncol. 2013 May;14(6):525-33. doi: 10.1016/S1470-2045(13)70122-0. Epub 2013 Apr 9. Lancet Oncol. 2013. PMID: 23578722 Clinical Trial.